• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.29% Nasdaq Down0.03%

    More On ADDXF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Addex Therapeutics Ltd. (ADDXF)

    -Other OTC
    3.38 0.00(0.00%) Mar 9
    Add to Portfolio
    ProfileGet Profile for:
    Addex Therapeutics Ltd.
    12, chemin des Aulx
    Plan-les-Ouates
    Geneva, 1228
    Switzerland - Map
    Phone: 41 22 884 1555
    Fax: 41 22 884 1556
    Website: http://www.addextherapeutics.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:5

    Business Summary 

    Addex Therapeutics Ltd, together with its subsidiaries, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia; ADX71149 for an undisclosed CNS disorders; ADX71441 for the treatment of Charcot-Marie-Tooth type 1A neuropathy; and ADX71441 for the treatments of addiction. The company focuses on the discovery of oral allosteric modulators of G-protein coupled receptors. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and collaboration with Dystonia Medical Research Foundation to prepare a phase IIa proof of concept clinical study in a form of dystonia. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Addex Therapeutics Ltd.

    Key Executives 
     PayExercised
    Mr. Timothy Dyer , 47
    Chief Exec. Officer
    711.00KN/A
    Dr. Sonia Maria Poli Ph.D., 50
    Chief Scientific Officer
    N/AN/A
    Dr. Bruno Bournique ,
    Head of Absorption, Distribution, Metabolism and Excretion (ADME) / Pharmacokinetics (PK)
    N/AN/A
    Dr. Werner Henrichi Ph.D., 72
    Consultant
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.